Concurrent bevacizumab with a sequential regimen of doxorubicin and cyclophosphamide followed by docetaxel and capecitabine as neoadjuvant therapy for HER2^- locally advanced breast cancer: A phase II trial of the NSABP foundation research group

Priya Rastogi, Marc E. Buyse, Sandra M. Swain, Samuel A. Jacobs, André Robidoux, Marcia K. Liepman, Eduardo R. Pajon, Philip A. Dy, Juan G. Posada, Marianne K. Melnik, Fanny Piette, Charles E. Geyer, Elfetherios P. Mamounas, Norman Wolmark

Internal Medicine

Research output: Contribution to journal › Article › peer-review

15 Scopus citations

Fingerprint

Dive into the research topics of 'Concurrent bevacizumab with a sequential regimen of doxorubicin and cyclophosphamide followed by docetaxel and capecitabine as neoadjuvant therapy for HER2^- locally advanced breast cancer: A phase II trial of the NSABP foundation research group'. Together they form a unique fingerprint.

Sort by
Weight
Alphabetically

Concurrent bevacizumab with a sequential regimen of doxorubicin and cyclophosphamide followed by docetaxel and capecitabine as neoadjuvant therapy for HER2- locally advanced breast cancer: A phase II trial of the NSABP foundation research group

Fingerprint

Medicine & Life Sciences

Concurrent bevacizumab with a sequential regimen of doxorubicin and cyclophosphamide followed by docetaxel and capecitabine as neoadjuvant therapy for HER2^- locally advanced breast cancer: A phase II trial of the NSABP foundation research group